
TGTX Valuation
TG Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
TGTX Relative Valuation
TGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TGTX is overvalued; if below, it's undervalued.
Historical Valuation
TG Therapeutics Inc (TGTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.75 is considered Undervalued compared with the five-year average of 19.12. The fair price of TG Therapeutics Inc (TGTX) is between 46.56 to 57.29 according to relative valuation methord. Compared to the current price of 28.96 USD , TG Therapeutics Inc is Undervalued By 37.8%.
Relative Value
Fair Zone
46.56-57.29
Current Price:28.96
37.8%
Undervalued
20.98
PE
1Y
3Y
5Y
Trailing
Forward
21.48
EV/EBITDA
TG Therapeutics Inc. (TGTX) has a current EV/EBITDA of 21.48. The 5-year average EV/EBITDA is -11.51. The thresholds are as follows: Strongly Undervalued below -184.57, Undervalued between -184.57 and -98.04, Fairly Valued between 75.01 and -98.04, Overvalued between 75.01 and 161.54, and Strongly Overvalued above 161.54. The current Forward EV/EBITDA of 21.48 falls within the Historic Trend Line -Fairly Valued range.
15.97
EV/EBIT
TG Therapeutics Inc. (TGTX) has a current EV/EBIT of 15.97. The 5-year average EV/EBIT is 11.73. The thresholds are as follows: Strongly Undervalued below -83.44, Undervalued between -83.44 and -35.85, Fairly Valued between 59.32 and -35.85, Overvalued between 59.32 and 106.91, and Strongly Overvalued above 106.91. The current Forward EV/EBIT of 15.97 falls within the Historic Trend Line -Fairly Valued range.
5.83
PS
TG Therapeutics Inc. (TGTX) has a current PS of 5.83. The 5-year average PS is 102.54. The thresholds are as follows: Strongly Undervalued below -299.68, Undervalued between -299.68 and -98.57, Fairly Valued between 303.64 and -98.57, Overvalued between 303.64 and 504.75, and Strongly Overvalued above 504.75. The current Forward PS of 5.83 falls within the Historic Trend Line -Fairly Valued range.
23.60
P/OCF
TG Therapeutics Inc. (TGTX) has a current P/OCF of 23.60. The 5-year average P/OCF is 24.75. The thresholds are as follows: Strongly Undervalued below -343.86, Undervalued between -343.86 and -159.55, Fairly Valued between 209.06 and -159.55, Overvalued between 209.06 and 393.36, and Strongly Overvalued above 393.36. The current Forward P/OCF of 23.60 falls within the Historic Trend Line -Fairly Valued range.
25.97
P/FCF
TG Therapeutics Inc. (TGTX) has a current P/FCF of 25.97. The 5-year average P/FCF is 26.88. The thresholds are as follows: Strongly Undervalued below -234.27, Undervalued between -234.27 and -103.70, Fairly Valued between 157.45 and -103.70, Overvalued between 157.45 and 288.03, and Strongly Overvalued above 288.03. The current Forward P/FCF of 25.97 falls within the Historic Trend Line -Fairly Valued range.
TG Therapeutics Inc (TGTX) has a current Price-to-Book (P/B) ratio of 15.22. Compared to its 3-year average P/B ratio of 30.21 , the current P/B ratio is approximately -49.63% higher. Relative to its 5-year average P/B ratio of 22.54, the current P/B ratio is about -32.50% higher. TG Therapeutics Inc (TGTX) has a Forward Free Cash Flow (FCF) yield of approximately -1.42%. Compared to its 3-year average FCF yield of -5.32%, the current FCF yield is approximately -73.27% lower. Relative to its 5-year average FCF yield of -8.62% , the current FCF yield is about -83.52% lower.
15.35
P/B
Median3y
30.21
Median5y
22.54
-1.40
FCF Yield
Median3y
-5.32
Median5y
-8.62
Competitors Valuation Multiple
The average P/S ratio for TGTX's competitors is 14.73, providing a benchmark for relative valuation. TG Therapeutics Inc Corp (TGTX) exhibits a P/S ratio of 5.75, which is -60.93% above the industry average. Given its robust revenue growth of 92.13%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TGTX increased by 23.29% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 9.36 to 19.97.
The secondary factor is the Revenue Growth, contributed 92.13%to the performance.
Overall, the performance of TGTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

PLXS
Plexus Corp
137.010
USD
-1.87%

GDS
GDS Holdings Ltd
34.560
USD
-1.48%

MSM
MSC Industrial Direct Co Inc
90.230
USD
-0.81%

MATX
Matson Inc
104.050
USD
-1.33%

AEIS
Advanced Energy Industries Inc
149.680
USD
-3.77%

BEPC
Brookfield Renewable Corp
33.700
USD
-2.09%

KRC
Kilroy Realty Corp
41.590
USD
-0.38%

PRIM
Primoris Services Corp
118.550
USD
-0.84%

ALGM
Allegro Microsystems Inc
30.850
USD
-3.62%

BRZE
Braze Inc
27.700
USD
+1.09%
FAQ

Is TG Therapeutics Inc (TGTX) currently overvalued or undervalued?
TG Therapeutics Inc (TGTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.75 is considered Undervalued compared with the five-year average of 19.12. The fair price of TG Therapeutics Inc (TGTX) is between 46.56 to 57.29 according to relative valuation methord. Compared to the current price of 28.96 USD , TG Therapeutics Inc is Undervalued By 37.80% .

What is TG Therapeutics Inc (TGTX) fair value?

How does TGTX's valuation metrics compare to the industry average?

What is the current P/B ratio for TG Therapeutics Inc (TGTX) as of Aug 30 2025?

What is the current FCF Yield for TG Therapeutics Inc (TGTX) as of Aug 30 2025?

What is the current Forward P/E ratio for TG Therapeutics Inc (TGTX) as of Aug 30 2025?
